191 related articles for article (PubMed ID: 23185851)
1. Treatment of localised prostate cancer: inform patients about adverse effects.
Prescrire Int; 2012 Oct; 21(131):247. PubMed ID: 23185851
[No Abstract] [Full Text] [Related]
2. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
3. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Gallina A
Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073
[No Abstract] [Full Text] [Related]
4. Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Yossepowitch O
Eur Urol; 2010 Apr; 57(4):639-40. PubMed ID: 19299071
[No Abstract] [Full Text] [Related]
5. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Ladjevardi S; Sandblom G; Berglund A; Varenhorst E
Eur Urol; 2010 Apr; 57(4):631-8. PubMed ID: 19299069
[TBL] [Abstract][Full Text] [Related]
6. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
Yamamoto S; Kawakami S; Yonese J; Fujii Y; Urakami S; Masuda H; Numao N; Ishikawa Y; Kohno A; Fukui I
Jpn J Clin Oncol; 2012 Jun; 42(6):541-7. PubMed ID: 22457326
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K
BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075
[TBL] [Abstract][Full Text] [Related]
9. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
Abrahamsson PA; Anderson J; Boccon-Gibod L; Schulman C; Studer UE; Wirth M
Eur Urol; 2005 Dec; 48(6):900-5. PubMed ID: 16257109
[TBL] [Abstract][Full Text] [Related]
10. Natural history of patients presenting biochemical recurrence after radical prostatectomy: some good news?
Guillonneau BD; Fizazi K
Eur Urol; 2011 Jun; 59(6):900-1. PubMed ID: 21419564
[No Abstract] [Full Text] [Related]
11. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
D'Amico AV; Chen MH
J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
[No Abstract] [Full Text] [Related]
12. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
14. Prognostic importance of small prostate size in men receiving definitive prostate brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Adamovich E; Wallner KE
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):396-401. PubMed ID: 22503528
[TBL] [Abstract][Full Text] [Related]
15. Controversies in prostate cancer radiotherapy: consensus development.
Lukka H; Warde P; Pickles T; Morton G; Brundage M; Souhami L;
Can J Urol; 2001 Aug; 8(4):1314-22. PubMed ID: 11564274
[TBL] [Abstract][Full Text] [Related]
16. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy.
Stone NN; Stone MM; Rosenstein BS; Unger P; Stock RG
J Urol; 2011 Feb; 185(2):495-500. PubMed ID: 21167528
[TBL] [Abstract][Full Text] [Related]
17. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
18. Intrafascial dissection significantly increases positive surgical margin and biochemical recurrence rates after robotic-assisted radical prostatectomy.
Mortezavi A; Hermanns T; Seifert HH; Wild PJ; Schmid DM; Sulser T; Eberli D
Urol Int; 2012; 89(1):17-24. PubMed ID: 22738925
[TBL] [Abstract][Full Text] [Related]
19. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting prostatic biopsy Gleason sum under grading.
Stackhouse DA; Sun L; Schroeck FR; Jayachandran J; Caire AA; Acholo CO; Robertson CN; Albala DM; Polascik TJ; Donatucci CF; Maloney KE; Moul JW
J Urol; 2009 Jul; 182(1):118-22; discussion 123-4. PubMed ID: 19447436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]